*Name*: Herpesvirus

Brief Introduction {#Sec1}
==================

*Herpesviridae* (HSV) is a DNA virus family that includes the order *Herpesvirales* and a number of species, some of which are addressed separately in this text. The *herpesviruses* cause both lytic and latent infections. *Herpesviruses* 1 and 2 infect the lung via the spread of virus from infected oral or esophageal lesions, by hematogenous dissemination, or via the transplantation of infected organs (Graham and Snell [@CR19]; Taplitz and Jordan [@CR33]; Tuxen et al. [@CR34]). *Herpesviruses* 6 and 8 can also produce lung pathology although their role in pathogenesis is not well elucidated.

Classification {#Sec2}
==============

In the 1970s, the genus *Herpesvirus* was elevated to the order *Herpesviridae*. This includes three families, three subfamilies plus one unassigned subfamily, 17 genera, 90 species, and more than 48 as yet unassigned viruses. The naming system specifies that each *herpesvirus* should be named after the taxon to which its primary host belongs. The *herpesvirus* is followed by an Arabic number, e.g., *Herpesvirus* 1. However, human *herpesviruses* represent an exception, as a number are better known by other names (e.g., Epstein--Barr virus) so that it is impractical to insist on a change into how they are referred. This has led to a dual nomenclature for some *herpesviruses*; however, all new *herpesviruses* described since this system was adopted are named in accordance with it. Nine *herpesviruses* currently are recognized to cause human disease.

Ultrastructure {#Sec3}
==============

*Herpesviruses* are large (100--110 nm) enveloped double-stranded DNA viruses with an icosahedral nucleocapsid (Fig. [6.1](#Fig1){ref-type="fig"}). The viral particle is invested with a lipid envelope as a result of viral budding at the level of the nuclear envelope (Whitley et al. [@CR35]). Fig. 6.1*Herpesvirus-1* ×7500 (Courtesy M. Selig)

Immunology {#Sec4}
==========

*Herpesvirus* types 1 and 2 can both infect the lung (Ramsey et al. [@CR28]). HSV-1 is the most frequent cause of primary disease, whereas HSV-2 generally results from viremic spread. All *herpesviruses* are *nuclear replicating*, i.e., the viral DNA is transcribed to mRNA within the infected cell's nucleus and the mRNA gene products promote the replication of the viral DNA. Infection is initiated when a viral particle contacts a cell with specific types of cell surface membrane receptors. Following binding of viral envelope glycoproteins to their receptors, the virion is internalized and dismantled, so that viral DNA can migrate to the cell nucleus where replication of viral DNA and transcription of viral genes occur.

During symptomatic infection, infected cells transcribe lytic viral genes. In some host cells, a small number of viral genes termed *latency-associated transcripts* (LAT) accumulate and allow the virus to persist in the host cell indefinitely. During latency, the infected host is asymptomatic, but reactivation of latent viruses can result in disease. In such case, the transcription of latency-associated LAT genes switches to that of *lytic* genes that lead to enhanced virus production and cell death. Symptoms and signs may include low-grade fever, headache, sore throat, and rash, as well as lymphadenopathy and reduced levels of circulating immune cells. Infection is long lived, as viral DNA persist in dormant states within sensory nerves and ganglia. HSV-1 reactivation begins in peripheral nerve cells, and viruses are transported via sensory nerve axons to mucosal surfaces, where they can produce vesicular eruptions.

Clinical Features {#Sec5}
=================

Young age, airway trauma, airway burns, prolonged mechanical ventilation, and immunosuppression are risk factors for developing herpetic pneumonia (Cherr et al. [@CR11]; Sherry et al. [@CR30]). Newborn infants are particularly at risk and may develop disseminated disease with pulmonary infiltrates and mortality rates (even following acyclovir therapy) approaching 30 % (Kimberlin [@CR23]). In adults, HSV is isolated from secretions in \~30 % of mechanically ventilated patients, and evidence suggests that *Herpesviruses* may be an important factor in severe exacerbations of chronic obstructive pulmonary disease (Gu and Korteweg [@CR20]). Dyspnea, cough, and hypoxemia are common in this setting. Acute Respiratory Distress Syndrome (ARDS) can develop with virulent herpetic infection, and bacterial and fungal superinfections are both common and can be fatal when they supervene. Herpesvirus can also complicate ARDS (Byers et al. [@CR5]).

The chest radiographic appearances of *Herpesvirus* infection range from mucosal thickening of the pulmonary airways, multifocal areas of consolidation, and diffuse bilateral pulmonary infiltrates. *Herpesvirus* tracheobronchial infections tend to complicate labial and esophageal disease with virus spreading via the aspiration of oropharyngeal secretions (Corey and Spear [@CR13]; Feldman and Stokes [@CR16]). Intubated patients receiving chronic ventilatory support are at risk as a consequence of local mucosal barotrauma from inflated endotracheal tubes.

Pathological Changes {#Sec6}
====================

The respiratory mucosa is the primary target, and *Herpesvirus* characteristically produces ulceration and extensive necrosis (Nash and Foley [@CR27]). The ballooning of infected cells, cell karyorrhexis, and piling up of the infected cells suggest the diagnosis. There may be a prominent neutrophilic response that mimics a pyogenic bacterial infection (Fig. [6.2](#Fig2){ref-type="fig"}). Immunosuppressed patients with *Herpesvirus* viremia may develop miliary foci of pulmonary hemorrhagic necrosis with prominent alveolar fibrin exudates (Graham [@CR18]) (Fig. [6.3](#Fig3){ref-type="fig"}). The foci of infection may be paucicellular although scattered neutrophilic exudates are frequently present. Diagnostic cytopathic changes may be difficult to identify but will usually be visualized after detailed examination of the involved foci. Fig. 6.2Neutrophilic exudates shows *Herpesvirus-1* infected cell (*arrow*) Fig. 6.3(**a**) Hemorrhagic necrotizing pneumonia in immunosuppressed patient with *Herpesvirus-1* viremia. (**b**) Multiple infected cells immunostaining for *Herpesvirus-1*

Diagnosis {#Sec7}
=========

The diagnosis of airway disease can be established by viral isolation from respiratory secretions, bronchoalveolar lavage fluids, or mucosal biopsies of ulcerated sites (Fig. [6.4](#Fig4){ref-type="fig"}). As immunohistochemistry shows antigenic overlap between HSV-1 and HSV-2 infections, PCR methods may be required for accurate speciation. Diagnostic cytopathic changes include the presence of either type A or type B Cowdry nuclear inclusions, molding of adjacent cells, and multikaryon formation (Fig. [6.5](#Fig5){ref-type="fig"}). When there is extensive necrosis, immunohistochemistry for herpes viral antigen will often demonstrate intense background staining. While this suggests the diagnosis, it can potentially obscure it (Strickler et al. [@CR32]) (Fig. [6.6b](#Fig6){ref-type="fig"}). The examination of paraffin-embedded tissues by electron microscopy can help to confirm the diagnosis. Fig. 6.4Herpetic inclusions in squamous respiratory epithelium of a chronically intubated patient Fig. 6.5Polykaryons with nuclear inclusions in herpetic pneumonia Fig. 6.6(**a**) Ulcerated tracheal lesion showing (**b**) intense immunostaining for *Herpesvirus-1.* The diagnosis was confirmed by ultrastructural examination demonstrating diagnostic virions

Differential Diagnosis {#Sec8}
======================

Necrotizing hemorrhagic pneumonias due to Herpesviruses are similar histopathologically to those associated with varicella zoster, adenovirus, and cytomegalovirus (CMV). Helpful in making the distinction are the location and character of the viral inclusions. For example, smudge cells are strongly suspicious of adenovirus while cytomegaly is more apt to be seen in CMV infection. Immunohistochemistry plays an important role and can help to refine the diagnosis.

Treatment {#Sec9}
=========

Therapy is based primarily on the usage of antiviral agents such as acyclovir, valacyclovir, and famciclovir. Drug-resistant strains may respond to fosecarnet. Fosecarnet has been found effective in some acyclovir-resistant patients. Supportive therapy, hydration, and treatment of associated bacterial infection are indicated in selected patients.

Clinicopathologic Capsule {#Sec10}
=========================

Herpesviruses can infect the lung as well as the mucosa of the tracheobronchial tree. Young age, airway trauma, prolonged mechanical ventilation, and immunosuppression are risk factors for development of herpetic infections. Biopsy samples from the respiratory mucosa showing ballooning of infected cells, cell karyorrhexis, and piling up of infected cells suggest the diagnosis. The diagnosis can be confirmed with appropriate immunohistochemical stains or by identification of Cowdry type A or B in infected cells. A rare and distinctive type of malignant lymphoma occurs in patients infected with Human Herpesvirus-8. This lymphoma has equally distinctive molecular features (mutations in the 5″ noncoding regions of bcl6) that help to make the diagnosis.

Variants {#Sec11}
========

Human Herpesvirus-6 {#Sec12}
-------------------

Studies of lung tissues and bronchoalveolar lavage specimens from patients with pneumonia have led some investigators to propose *Human Herpesvirus 6* (HHV-6) as a clinical cause of pneumonia (Cone et al. [@CR12]). Cases should be referred to as "*HHV-6-*associated" pneumonia. Both mild and severe cases of pneumonia and bronchiolitis obliterans organizing pneumonia (BOOP) have been reported for HHV-6 infection occurring in immunosuppressed individuals with HIV or following bone marrow transplantation. No systematic evaluation of treatment regimens is currently available, and controlled prospective studies are required to confirm *HHV-6* as a primary pulmonary pathogen.

Human Herpesvirus-8 {#Sec13}
-------------------

In addition to its role in Kaposi's sarcoma and multicentric Castleman's disease, HHV-8 has been suggested as a cause of interstitial pneumonitis. Primary effusion lymphoma, previously called body-cavity-based lymphoma, is a rare, distinctive type of HHV8+ diffuse large B-cell lymphoma characterized by lymphomatous effusions involving pleural, pericardial, or peritoneal cavities unaccompanied by a solid mass (Ansari et al. [@CR2]; Cesarman et al. [@CR9]; Said and Cesarman [@CR29]). Here we discuss only primary effusion lymphoma.

Primary effusion lymphoma (PEL) affects young and middle-aged adults, with males more often affected than females. Nearly all patients are also HIV positive. They present late in the course of HIV infection and are profoundly immunocompromised at the time of presentation. Patients who are HIV negative are mostly elderly and often of Mediterranean origin (Ferry et al. [@CR17]; Klepfish et al. [@CR25]; Nador et al. [@CR26]). Patients present with a pleural effusion, pericardial effusion, or ascites. By definition, there is no discrete contiguous lymphomatous mass associated with the effusion. PEL has a poor prognosis, although among HIV+ patients, the outcome may be better for those receiving highly active antiretroviral therapy (HAART) (Boulanger et al. [@CR4]). Death is due to lymphoma, complicated by opportunistic infection and/or Kaposi's sarcoma (Carbone [@CR6]).

Pathologic Features of Primary Effusion Lymphoma {#Sec14}
================================================

The neoplastic cells of primary effusion lymphoma are either uniform and immunoblast like or very large and pleomorphic (Fig. [6.7a, b](#Fig7){ref-type="fig"}). Some are multinucleated and may resemble Reed--Sternberg cells. Neoplastic cells express CD45, as well as activation antigens, including CD30, without expression of B-cell-specific markers. Despite the absence of B-cell antigens, immunoglobulin heavy and light chains are clonally rearranged, thereby supporting a B lineage. Occasionally there is aberrant expression of T-cell-associated antigens (Said and Cesarman [@CR29]). Tumor cells are often coinfected with EBV. Like HHV-8, EBV is a gamma *herpesvirus* closely related to HHV-8 (Cesarman et al. [@CR9]; Cesarman and Knowles [@CR8]; Chadburn et al. [@CR10]). The neoplastic cells are also bcl6-, MUM1/IRF4+, and CD138+, corresponding to a late stage in B-cell differentiation (Carbone et al. [@CR7]). MUM1/IRF4 has been shown to downregulate cellular response to interferon, at least in vitro. It is possible that MUM1/IRF4 expression by the neoplastic cells plays a role in allowing the virally infected tumor cells to escape from interferon-mediated control (Carbone et al. [@CR7]). HHV-8 may also downregulate expression of major histocompatibility complex (MHC) class I surface molecules, allowing HHV8-infected cells to escape killing by cytotoxic T cells (Sirianni et al. [@CR31]). HHV8 infection may be associated with impaired natural killer (NK) cell activity (Sirianni et al. [@CR31]). These features, in combination with the tendency of primary effusion lymphoma to occur at a late stage in the course of HIV infection, contribute to the very poor prognosis associated with this lymphoma.Fig. 6.7(**a**) Primary effusion lymphoma showing large malignant lymphoid cells that (**b**) express HHV-8

Primary effusion lymphoma has distinctive molecular features. It is frequently associated with mutations in the 5′ noncoding regions of *BCL6* (Antinori et al. [@CR3]) as well as in the immunoglobulin gene variable (*IGV*) regions (Hamoudi et al. [@CR21]). *BCL6* and *IGV* mutations are considered to indicate transition of B cells through the germinal center, and in conjunction with the immunophenotype, the genetic changes provide additional support for a late, post-germinal center stage of maturation for the neoplastic cells of primary effusion lymphoma in most cases. Gene expression profile analysis shows that primary effusion lymphoma shares features of AIDS-associated immunoblastic lymphoma and plasma cell myeloma and is quite different from other types of B-cell lymphomas (Jenner and Boshoff [@CR22]; Klein et al. [@CR24]). There is in addition a specific set of genes unique to primary effusion lymphoma (Klein et al. [@CR24]). Thus, both immunophenotype and genetic features indicate that the neoplastic cells of primary effusion lymphoma correspond to a late stage in B-cell differentiation. It is proposed that HHV8, utilizing some of the genes in the B-cell program of its host, drives the cells it occupies toward plasma cells (Jenner and Boshoff [@CR22]).

Cases of HHV8+ lymphoma with morphology and immunophenotypic and genetic features similar to those of primary effusion lymphoma but producing mass lesions in lymph nodes or in extranodal sites have been described (Anagnostopoulos et al. [@CR1]; Carbone [@CR6]; Chadburn et al. [@CR10]; DePond et al. [@CR15]). These have been called HHV-8+ or KSHV+ solid lymphomas or extracavitary primary effusion lymphomas (Carbone [@CR6]; Chadburn et al. [@CR10]) or KSHV+ solid immunoblastic/plasmablastic diffuse large B-cell lymphomas (Deloose et al. [@CR14]). Some patients with "solid lymphomas" also develop HHV-8+ effusion lymphomas. HHV-8+ large B-cell lymphomas can also evolve out of HHV-8+ multicentric Castleman's disease; these lymphomas mainly affect HIV+ patients and primarily involve lymph nodes and spleen. They are typically composed of monotypic cytoplasmic IgM+, EBV−, HHV8+ plasmablasts (Anagnostopoulos et al. [@CR1]).
